Nureca Ltd.

288.30 -0.30 ▼-0.1%

02 May 2024, 04:01:00 PM
Volume: 4,164

Company Profile

Sector Healthcare Sector Icon Healthcare Compare with Sector peers
Industry Medical Equipment/Supplies/Accessories Industry Icon Medical Equipment/Supplies/Accessories Compare with Industry peers
Website http://www.nureca.com
Market Cap 288.31 Cr.
Enterprise Value(EV) 234.14 Cr. 2023-09
Financial Indicators
Earnings per share (EPS) 0.82 Trailing Twelve Months Ending 2023-12
Price-Earning Ratio (PE) 350.74 Trailing Twelve Months Ending 2023-12
Industry PE 59.14 Trailing Twelve Months Ending 2023-12
Book Value / Share 197.20 Trailing Twelve Months Ending 2023-12
Price to Book Value 1.46 Calculated using Price: 288.30
Dividend Yield 0.00 Period Ending 2023-03
No. of Shares Subscribed 1.00 Cr. 10,000,175 Shares
FaceValue 10
About Nureca Ltd.
Nureca is a B2C company engaged in the business of home healthcare and wellness products, which offers quality, durability, functionality, usability and innovative designs. It enables its customers with tools to help them monitor chronic ailments and other diseases, to improve their lifestyle. It is a digital first company wherein it sells its products through online channel partners such as e-commerce players, distributors and retailer. Further, it also sells its products through its own website drtrust.in.

Nureca Ltd. Delivery

Delivered Qty
Traded Qty

Nureca Ltd. Performance

1 Day
-0.10%
1 Week
-1.39%
1 Month
+12.99%
3 Month
-22.03%
6 Month
-13.54%
1 Year
-13.51%
2 Year
-77.78%
5 Year
10 Year

Nureca Ltd. Fundamental Ratios

6 years 2018-03 2019-03 2020-03 2021-03 2022-03 2023-03
Return on Equity (%) 426.3 162.03 61.23 52.39 24.55 -4.14
Return on Capital Employed (%) 255.06 179.97 56.7 67.61 33.57 -5.17
Return on Assets (%) 44.35 40.78 22.3 41.38 20.33 -3.62

Nureca Ltd. Balance Sheet

Particulars 7 years 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-09* Rs. Cr.
Shh. Funds 2 8 15 163 203 195 197
Non Curr. Liab. 0 0 9 3 4 0 0
Curr. Liab. 5 15 10 24 45 9 9
Minority Int.
Equity & Liab. 7 24 34 190 252 204 207
Non Curr. Assets 0 1 1 4 13 17 12
Curr. Assets 7 23 33 186 239 187 195
Misc. Exp. not W/O
Total Assets 7 24 34 190 252 204 207

Nureca Ltd. Profit and Loss

Particulars 7 years 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-12 Rs. Cr. TTM
Net Sales 20 62 99 213 256 111 96
Other Income 0 0 0 3 8 7 14
Total Income 20 62 99 216 263 118 110
Total Expenditure -16 -53 -90 -152 -200 -126 -105
PBIDT 4 9 10 64 63 -8 5
Interest 0 0 -1 -2 -1 0 0
Depreciation 0 0 0 0 -1 -2 -2
Taxation -1 -3 -2 -16 -16 2 -1
Exceptional Items
PAT 3 6 6 46 45 -8 1
Minority Interest
Share Associate
Other Related Items
Consolidated Net Profit 3 6 6 46 45 -8 1
Adjusted EPS 445 889 914 46 45 -8 1

Nureca Ltd. Cash Flow

Particulars 6 years 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr.
Cash Fr. Operatn. 0 0 -8 35 1 10
Cash Fr. Inv. 0 0 0 -110 -3 -16
Cash Fr. Finan. 0 0 8 92 -7 -2
Net Change 0 0 0 17 -9 -8
Cash & Cash Eqvt 0 0 0 17 8 1

Nureca Ltd. Shareholding Pattern

9 Qtrs 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%) 2023-03 (%) 2023-06 (%) 2023-09 (%) 2023-12 (%) 2024-03 (%)
Promoter 70.00 70.00 70.00 62.98 62.98 62.98 63.24 63.24 63.24
Public 30.00 30.00 30.00 37.02 37.02 37.02 36.76 36.76 36.76
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
No. of Shareholders (in Lacs)

Nureca Ltd. Announcements

Tue, 16 Apr 2024
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate.

Sr. No. Particulars Details
1Name of CompanyNureca Ltd
2CIN NO.L24304MH2016PLC320868
3 Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr) 0.40
4Highest Credit Rating during the previous FY NA
4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable
5Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the frameworkBSE


We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No



Name of the Company Secretary: Chetna Anand
Designation: Company Secretary and Compliance Officer
EmailId: cs@nureca.com
Name of the Chief Financial Officer: Naresh Gupta
Designation: Chief Financial Officer
EmailId: naresh.gupta@nureca.com

Date: 16/04/2024

Note: In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
Wed, 10 Apr 2024
Compliance Under Regulation 40(10) Of The Securities Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015
Please find enclosed herewith copy of Certificate received from a Company Secretary in Practice as required under 40(9) of the Securities Exchange Board of India (Listing obligations and Disclosure Requirements) Regulations 2015 for the year ended March 31 2024.
Tue, 09 Apr 2024
Compliance Certificate - Regulation 7 (3) Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015.
Please find attached Compliance Certificate-Regulation 7(3) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015.

Nureca Ltd. Technical Scans

Tue, 30 Apr 2024
Opening at High Opening at High
Close Within 52 Week Low Zone Close Within 52 Week Low Zone
High Increase in 1 Month High Increase in 1 Month
High Decrease in 3 Months High Decrease in 3 Months
High Decrease in 2 Years High Decrease in 2 Years

Nureca Ltd. Related Stocks

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 365,874.59 1,520.00 +1.2%
Cipla Ltd. 114,557.24 1,419.55 +1.3%
Divi's Laboratories Ltd. 104,804.34 3,956.05 -1.1%
Dr. Reddy's Laboratories Ltd. 104,403.21 6,260.00 +0.9%
Zydus Lifesciences Ltd. 99,214.67 988.00 +3.6%
Mankind Pharma Ltd. 94,488.80 2,340.20 -1.1%
Torrent Pharmaceuticals Ltd. 90,090.79 2,673.75 +1.3%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 41.08 1,520.00 +1.2%
Cipla Ltd. Consolidated 2023-12 30.89 1,419.55 +1.3%
Divi's Laboratories Ltd. Consolidated 2023-12 75.78 3,956.05 -1.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 19.97 6,260.00 +0.9%
Zydus Lifesciences Ltd. Consolidated 2023-12 33.36 988.00 +3.6%
Mankind Pharma Ltd. Consolidated 2023-12 54.71 2,340.20 -1.1%
Torrent Pharmaceuticals Ltd. Consolidated 2023-12 60.30 2,673.75 +1.3%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 5.86 1,520.00 +1.2%
Cipla Ltd. Consolidated 2023-12 4.42 1,419.55 +1.3%
Divi's Laboratories Ltd. Consolidated 2023-12 8.04 3,956.05 -1.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 3.88 6,260.00 +0.9%
Zydus Lifesciences Ltd. Consolidated 2023-12 5.26 988.00 +3.6%
Mankind Pharma Ltd. Consolidated 2023-12 10.64 2,340.20 -1.1%
Torrent Pharmaceuticals Ltd. Consolidated 2023-12 12.60 2,673.75 +1.3%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 0.11 1,520.00 +1.2%
Cipla Ltd. Consolidated 2023-03 0.02 1,419.55 +1.3%
Divi's Laboratories Ltd. Consolidated 2023-03 0.00 3,956.05 -1.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 0.06 6,260.00 +0.9%
Zydus Lifesciences Ltd. Consolidated 2023-03 0.07 988.00 +3.6%
Mankind Pharma Ltd. Consolidated 2023-03 0.02 2,340.20 -1.1%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 0.85 2,673.75 +1.3%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,520.00 +1.2%
Cipla Ltd. Consolidated 2023-03 12.85 1,419.55 +1.3%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,956.05 -1.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 6,260.00 +0.9%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 988.00 +3.6%
Mankind Pharma Ltd. Consolidated 2023-03 19.27 2,340.20 -1.1%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 20.50 2,673.75 +1.3%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,520.00 +1.2%
Cipla Ltd. Consolidated 2023-03 12.85 1,419.55 +1.3%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,956.05 -1.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 6,260.00 +0.9%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 988.00 +3.6%
Mankind Pharma Ltd. Consolidated 2023-03 19.27 2,340.20 -1.1%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 20.50 2,673.75 +1.3%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 43,885.68 1,520.00 +1.2%
Cipla Ltd. Consolidated 2023-03 22,753.12 1,419.55 +1.3%
Divi's Laboratories Ltd. Consolidated 2023-03 7,767.51 3,956.05 -1.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 24,669.70 6,260.00 +0.9%
Zydus Lifesciences Ltd. Consolidated 2023-03 17,237.40 988.00 +3.6%
Mankind Pharma Ltd. Consolidated 2023-03 8,749.43 2,340.20 -1.1%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 9,620.15 2,673.75 +1.3%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 8,560.84 1,520.00 +1.2%
Cipla Ltd. Consolidated 2023-03 2,835.49 1,419.55 +1.3%
Divi's Laboratories Ltd. Consolidated 2023-03 1,823.38 3,956.05 -1.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 4,507.30 6,260.00 +0.9%
Zydus Lifesciences Ltd. Consolidated 2023-03 2,001.90 988.00 +3.6%
Mankind Pharma Ltd. Consolidated 2023-03 1,309.68 2,340.20 -1.1%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 1,245.23 2,673.75 +1.3%

Nureca Ltd. FAQ's

What is Nureca Ltd. share price?

Can I buy Nureca Ltd. shares now?

What is the Market Cap of Nureca Ltd.?

What are the key metrics to analyse Nureca Ltd.?

What is the 52 Week High and Low of Nureca Ltd.?

What is the trend of Nureca Ltd. share price?